Is a Surprise Coming for Acadia Pharmaceuticals (ACAD) This Earnings Season?Zacks Investment Research • 11/01/22
Acadia Pharmaceuticals Announces Planned Retirement of President Srdjan (Serge) StankovicBusiness Wire • 10/27/22
Acadia Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022Business Wire • 10/20/22
Acadia Pharmaceuticals Appoints Adora Ndu, Pharm.D., J.D. to its Board of DirectorsBusiness Wire • 10/13/22
Alzamend Neuro Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimer's SubjectsBusiness Wire • 10/05/22
Acadia Pharmaceuticals Recognizes Rett Syndrome Awareness Month and Launches New Awareness Campaign, Rett RevealedBusiness Wire • 10/04/22
Alzamend Neuro Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer's TypeBusiness Wire • 09/29/22
Acadia Pharmaceuticals Announces Trofinetide New Drug Application for the Treatment of Rett Syndrome has been Accepted for Filing and Review by U.S. FDABusiness Wire • 09/12/22
Acadia (ACAD) Down 0.6% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 09/07/22
Wall Street Analysts Believe Acadia (ACAD) Could Rally 26%: Here's is How to TradeZacks Investment Research • 08/30/22
ACADIA Pharmaceuticals, Inc. (ACAD) CEO Stephen Davis on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/09/22
Acadia Pharmaceuticals (ACAD) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/08/22
Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Alzheimer's Disease PsychosisBusiness Wire • 08/05/22
Acadia Pharmaceuticals to Announce Second Quarter 2022 Financial Results on August 8, 2022Business Wire • 07/25/22
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline - ACADPRNewsWire • 07/22/22
Acadia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Trofinetide for the Treatment of Rett SyndromeBusiness Wire • 07/18/22